Remote Monitoring and Symptom Management Digital Application
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Patrick C. Johnson, MD
- Study ID
- NCT07553572
- Status
- Recruiting
Conditions
- Breast Cancer (Locally Advanced or Metastatic)
- Colorectal Cancer
- Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ASSIST phone application — OTHERThe intervention consists of a smartphone-based application that provides personalized support using AI during cancer treatment. Patients will also receive standard care from their oncology team, including routine symptom management and supportive care measures.
Study Details
The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The main question\[s\] it aims to answer are: Is ASSIST feasible for patients (meaning can it be used by patients)? Is ASSIST acceptable to patients (meaning do patients like it)? Researchers will compare the ASSIST phone application to see how it compares to usual clinical care. Participants on the ASSIST arm will use the ASSIST phone application for 12 weeks, and participants in both groups will complete surveys.
Key Dates
- Start date
- Apr 14, 2026
- Status verified
- Apr 2026
- Primary completion
- Nov 30, 2026
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: ASSIST phone application armThe intervention consists of a smartphone-based application that provides personalized support using AI during cancer treatment. Patients will also receive standard care from their oncology team, including routine symptom management and supportive care measures.
- No Intervention: Usual CarePatients in the usual care group will receive standard care from their oncology team, including routine symptom management and supportive care measures.
Primary Outcome Measure
Recruitment Rates [ Time Frame: From enrollment to end of intervention at 12 weeks ]
Central Contacts
- Patrick C Johnson, MD6177244000
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersPHASE1/PHASE2 · Recruiting · Lumicell, Inc. · Boston, Massachusetts
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Miami, Florida
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California